Products
| Product | Strength | Pack Size |
|---|---|---|
| Amiodarone Hydrochloride Tablets | 200mg | 20 tablets / box 30 tablets / box 60 tablets / box |
| Propafenone Hydrochloride Tablets | 150mg | 840 tablets / box |
* The above product list shows our products which are approved by Hong Kong Department of Health only. It does not mean that all products are already placed in the market. For any product or business enquiries please contact us at ichk@ichk.org or (852) 2891 0581 for further details.
Arrhythmia
Arrhythmia refers to the change from normal heart rhythm. This might cause the heart to beat too fast (tachycardia), too slow (bradycardia) or in an irregular pattern (fibrillation). Patients suffering from arrhythmia may experience shortness of breath, fatigue, palpitations and dizziness. It is in particularly common in those with hypertension, heart failure or have undergone prior heart surgery.
Antiarrhythmic agent
One of the possible ways to treat arrhythmia is to control the pattern of conduction. This is particularly important to those who are hemodynamically unstable or with exacerbating heart failure. Amiodarone is a rhythm control agent commonly used. It is a class III antiarrhythmic agent that inhibits the stimulation of electrical signals conduction for heart beat. Although amiodarone is not FDA approved in the USA for rhythm control, it is widely used in clinical setting.
Amiodarone is more effective than a rate control drug or placebo in achieving sinus rhythm in patients with persistent Atrial Fibrillation (AF). It has been shown that 77% of patients with a median follow up of 46 months had effective control of Atrial Fibrillation with no deaths, hospitalizations or late cardioversions reported. Amiodarone is thus commonly used to improve the quality of life and exercise performance of patients with uncontrollable symptoms of AF.
In addition, Amiodarone is useful to those with Congestive Heart Failure (CHF). It has been shown that amiodarone leads to a decrease in BNP level. BNP is a biomarker in CHF. An increase in its level indicates the worsening of the heart. Amiodarone is thus available to help restore sinus rhythm in paroxysmal and persistent Atrial Fibrillation patients with CHF.
Patients should be reminded to have a thorough assessment of hepatic, thyroid and pulmonary function on a regular basis while taking amiodarone to detect any symptoms that suggest possible organ toxicity.
Antiarrhythmic agent
One of the possible ways to treat arrhythmia is to control the pattern of conduction. This is particularly important to those who are hemodynamically unstable or with exacerbating heart failure. Amiodarone is a rhythm control agent commonly used. It is a class III antiarrhythmic agent that inhibits the stimulation of electrical signals conduction for heart beat. Although amiodarone is not FDA approved in the USA for rhythm control, it is widely used in clinical setting.
Amiodarone is more effective than a rate control drug or placebo in achieving sinus rhythm in patients with persistent Atrial Fibrillation (AF). It has been shown that 77% of patients with a median follow up of 46 months had effective control of Atrial Fibrillation with no deaths, hospitalizations or late cardioversions reported. Amiodarone is thus commonly used to improve the quality of life and exercise performance of patients with uncontrollable symptoms of AF.
In addition, Amiodarone is useful to those with Congestive Heart Failure (CHF). It has been shown that amiodarone leads to a decrease in BNP level. BNP is a biomarker in CHF. An increase in its level indicates the worsening of the heart. Amiodarone is thus available to help restore sinus rhythm in paroxysmal and persistent Atrial Fibrillation patients with CHF.
Patients should be reminded to have a thorough assessment of hepatic, thyroid and pulmonary function on a regular basis while taking amiodarone to detect any symptoms that suggest possible organ toxicity.